REGENXBIO Inc.
RGNX Healthcare Biotechnology
REGENXBIO Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.4 million, up 104.5% from fiscal 2024. In the quarter to June 2026, revenue grew 405.7%, EPS grew 131.2% and free cash flow fell 26.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow RGNX
REGENXBIO Inc. (RGNX) EV/Sales
As of 16 October 2026, REGENXBIO Inc. (RGNX) trades at a EV/Sales of 1.5×. Over the past ten years it has ranged from −40.0× (October 2015) to 119× (March 2017); the current reading is higher than 16% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.0× | 64.72% |
| FY2024 | 1.8× | (68.72%) |
| FY2023 | 5.9× | 10.65% |
| FY2022 | 5.3× | 168.03% |
| FY2021 | 2.0× | (74.81%) |
| FY2020 | 7.9× | (77.05%) |
| FY2019 | 34.4× | 591.10% |
| FY2018 | 5.0× | (94.10%) |
| FY2017 | 84.4× | (2.90%) |
| FY2016 | 86.9× | 1,630.31% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.1× | (8.99%) |
| Mar 2026 | 3.4× | 10.33% |
| Dec 2025 | 3.0× | 112.93% |
| Sep 2025 | 1.4× | 111.47% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ARVN Arvinas, Inc. compare | −0.4× |
| MNPR Monopar Therapeutics Inc. compare | n/m |
| NGNE Neurogene Inc. compare | n/m |
| RGNX REGENXBIO Inc. | 1.5× |
| ALLO Allogene Therapeutics, Inc. compare | 20.9× |
| CBIO Crescent Biopharma, Inc. compare | 187× |
| ENTX Entera Bio Ltd. compare | 541× |
| ALT Altimmune, Inc. compare | 2,534× |
| YDES YD Bio Limited compare | — |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)